GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 15991 participants.
Also called NCT01813435
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 15,991 participants
- Registry
-
NCT01813435
-
- Other papers using this trial's data
- Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial
- Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes: A Post Hoc Analysis of the Randomized GLOBAL LEADERS Trial
- Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-Specified Analysis of the GLOBAL LEADERS Trial
- Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI
- Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention
- Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial
- Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial
- Parsimonious versus extensive bleeding score: can we simplify risk stratification after percutaneous coronary intervention and reduce bleeding events by de-escalation of the antiplatelet strategy?
- Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial
- Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS)
- The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial
- Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Denmark, France, Germany, Hungary, Italy, Netherlands, Poland, Portugal, Singapore, Spain, Switzerland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01813435. Randomized; no masking; primary purpose treatment. Start 2013-07-01 (actual); primary completion 2015-11-09 (actual). Results posted on 2019-07-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation
- Intervention (Drug)
- Ticagrelor
- Intervention (Drug)
- Acetylsalicylic Acid
- Intervention (Drug)
- Clopidogrel
- Lead sponsor
- ECRI bv
- Collaborator
- Biosensors International
- Collaborator
- AstraZeneca
- Collaborator
- The Medicines Company
Record details
- Record id
cardio:ct-nct01813435- Content hash
d0f4203502331f19178ef30ffd67e115ad4fea94d822a12d87afbfa69b5bd36c